Skip to main content
. 2022 Jan 1;12(1):167–185. doi: 10.7150/thno.61209

Figure 7.

Figure 7

Gene signature development in ex-vivo expanded TILs treated with Ibrutinib and rapamycin. (A) Heatmap of the top ranked genes expressed in TILs following expansion ex vivo in response to chronic TCR-dependent activation in the presence of Ibrutinib and rapamycin (Ibr/Rap) VS. DMSO vehicle. Each column represents an individual patient. (B) Box plots comparing the change in gene signature pathways between Ibr/Rap and Vehicle (DMSO) treated groups.